{"generic":"Icatibant Acetate","drugs":["Firazyr","Icatibant Acetate"],"mono":{"0":{"id":"930003-s-0","title":"Generic Names","mono":"Icatibant Acetate"},"1":{"id":"930003-s-1","title":"Dosing and Indications","sub":[{"id":"930003-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>ACE inhibitor-induced angioedema:<\/b> 30 mg SUBQ (study dose)<\/li><li><b>Hereditary angioedema, Acute Attacks:<\/b> 30 mg SUBQ over at least 30 seconds in the abdominal area; additional doses of 30 mg may be administered at intervals of at least 6 hours if attack persists or symptoms recur; MAX 90 mg\/24 hours<\/li><\/ul>"},{"id":"930003-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness in patients below 18 years of age have not been established "},{"id":"930003-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Geriatric:<\/b> No dosage adjustment is recommended<\/li><li><b>Renal impairment:<\/b> No dosage adjustment is required<\/li><li><b>Hepatic impairment:<\/b> No dosage adjustment is required<\/li><\/ul>"},{"id":"930003-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hereditary angioedema, Acute Attacks<br\/><b>Non-FDA Labeled Indications<\/b><br\/>ACE inhibitor-induced angioedema<br\/>"}]},"3":{"id":"930003-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930003-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930003-s-3-10","title":"Precautions","mono":"<ul><li>airway obstruction during acute laryngeal attacks may occur; immediate medical attention required in addition to treatment with icatibant<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930003-s-3-11","title":"Pregnancy Category","mono":"Icatibant: C (FDA)<br\/>"},{"id":"930003-s-3-12","title":"Breast Feeding","mono":"Icatibant: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930003-s-4","title":"Drug Interactions","sub":{"2":{"id":"930003-s-4-15","title":"Moderate","mono":"<ul>Captopril (established)<\/ul>"}}},"5":{"id":"930003-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (97%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, AST\/SGOT level raised<\/li><li><b>Neurologic:<\/b>Dizziness (3%)<\/li><li><b>Other:<\/b>Fever (4%)<\/li><\/ul>"},"6":{"id":"930003-s-6","title":"Drug Name Info","sub":{"0":{"id":"930003-s-6-17","title":"US Trade Names","mono":"Firazyr<br\/>"},"2":{"id":"930003-s-6-19","title":"Class","mono":"Immune Modulator<br\/>"},"3":{"id":"930003-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930003-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930003-s-7","title":"Mechanism Of Action","mono":"Icatibant is a bradykinin B2 receptor antagonist. It inhibits bradykinin from binding the bradykinin B2 receptor and therefore treats the symptoms of an acute hereditary angioedema attack.<br\/>"},"8":{"id":"930003-s-8","title":"Pharmacokinetics","sub":[{"id":"930003-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 0.75 hour<\/li><li>Bioavailability, SubQ: 97%<\/li><\/ul>"},{"id":"930003-s-8-24","title":"Distribution","mono":"Vd: 29 L <br\/>"},{"id":"930003-s-8-25","title":"Metabolism","mono":"Extensive via proteolytic enzymes <br\/>"},{"id":"930003-s-8-26","title":"Excretion","mono":"<ul><li>Renal excretion: inactive metabolites; less than 10% unchanged<\/li><li>Total body: 245 mL\/min<\/li><\/ul>"},{"id":"930003-s-8-27","title":"Elimination Half Life","mono":"1.4 hours <br\/>"}]},"9":{"id":"930003-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Use the provided 25 gauge needle, do not use a different needle<\/li><li>Administer SUBQ over at least 30 seconds into the abdomen<\/li><\/ul>"},"10":{"id":"930003-s-10","title":"Monitoring","mono":"improvement in symptoms of acute attacks of hereditary angioedema is indicative of efficacy<br\/>"},"11":{"id":"930003-s-11","title":"How Supplied","mono":"<b>Firazyr<\/b><br\/>Subcutaneous Solution: 10 MG\/ML<br\/>"},"13":{"id":"930003-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to avoid activities requiring mental alertness or coordination until drug effects are realized as drug may cause tiredness, drowsiness, and dizziness.<\/li><li>Drug may cause injection-site reactions, pyrexia, and rash.<\/li><li>Advise patient using drug for acute laryngeal symptoms to seek immediate medical attention after administering drug.<\/li><li>Instruct patient that additional doses may be administered at intervals of at least 6 hours if symptoms recur or response is inadequate. Patient should not use more than 3 doses in 24 hours.<\/li><\/ul>"}}}